280 related articles for article (PubMed ID: 1571539)
1. Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia.
Robertson MJ; Soiffer RJ; Freedman AS; Rabinowe SL; Anderson KC; Ervin TJ; Murray C; Dear K; Griffin JD; Nadler LM
Blood; 1992 May; 79(9):2229-36. PubMed ID: 1571539
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD33 monoclonal antibody and etoposide/cytosine arabinoside combinations for the ex vivo purification of bone marrow in acute nonlymphocytic leukemia.
Stiff PJ; Schulz WC; Bishop M; Marks L
Blood; 1991 Jan; 77(2):355-62. PubMed ID: 1985700
[TBL] [Abstract][Full Text] [Related]
3. Autologous bone marrow transplantation in high-risk remission B-lineage acute lymphoblastic leukemia using a cocktail of three monoclonal antibodies (BA-1/CD24, BA-2/CD9, and BA-3/CD10) plus complement and 4-hydroperoxycyclophosphamide for ex vivo bone marrow purging.
Uckun FM; Kersey JH; Haake R; Weisdorf D; Ramsay NK
Blood; 1992 Feb; 79(4):1094-104. PubMed ID: 1531306
[TBL] [Abstract][Full Text] [Related]
4. Engraftment of leukocyte subsets following autologous bone marrow transplantation in acute myeloid leukemia using anti-myeloid (CD14 and CD15) monoclonal antibody-purged bone marrow.
Ericson SG; Colby E; Welch L; Ball ED
Bone Marrow Transplant; 1992 Feb; 9(2):129-37. PubMed ID: 1373982
[TBL] [Abstract][Full Text] [Related]
5. Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells.
Roy DC; Griffin JD; Belvin M; Blättler WA; Lambert JM; Ritz J
Blood; 1991 Jun; 77(11):2404-12. PubMed ID: 2039821
[TBL] [Abstract][Full Text] [Related]
6. Effects of anti-CD33 blocked ricin immunotoxin on the capacity of CD34+ human marrow cells to establish in vitro hematopoiesis in long-term marrow cultures.
La Russa VF; Griffin JD; Kessler SW; Cutting MA; Knight RD; Blattler WA; Lambert JM; Wright DG
Exp Hematol; 1992 May; 20(4):442-8. PubMed ID: 1373688
[TBL] [Abstract][Full Text] [Related]
7. Improved outcome for high-risk acute myeloid leukemia patients using autologous bone marrow transplantation and monoclonal antibody-purged bone marrow.
Selvaggi KJ; Wilson JW; Mills LE; Cornwell GG; Hurd D; Dodge W; Gingrich R; Martin SE; McMillan R; Miller W
Blood; 1994 Mar; 83(6):1698-705. PubMed ID: 8123862
[TBL] [Abstract][Full Text] [Related]
8. Busulfan/etoposide--initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia.
Chao NJ; Stein AS; Long GD; Negrin RS; Amylon MD; Wong RM; Forman SJ; Blume KG
Blood; 1993 Jan; 81(2):319-23. PubMed ID: 8422458
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel.
Duzkale H; Pagliaro LC; Rosenblum MG; Varan A; Liu B; Reuben J; Wierda WG; Korbling M; McMannis JD; Glassman AB; Scheinberg DA; Freireich EJ
Biol Blood Marrow Transplant; 2003 Jun; 9(6):364-72. PubMed ID: 12813444
[TBL] [Abstract][Full Text] [Related]
10. Developmental hierarchy during early human B-cell ontogeny after autologous bone marrow transplantation using autografts depleted of CD19+ B-cell precursors by an anti-CD19 pan-B-cell immunotoxin containing pokeweed antiviral protein.
Uckun FM; Haissig S; Ledbetter JA; Fidler P; Myers DE; Kuebelbeck V; Weisdorf D; Gajl-Peczalska K; Kersey JH; Ramsay NK
Blood; 1992 Jun; 79(12):3369-79. PubMed ID: 1375851
[TBL] [Abstract][Full Text] [Related]
11. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity.
Caron PC; Jurcic JG; Scott AM; Finn RD; Divgi CR; Graham MC; Jureidini IM; Sgouros G; Tyson D; Old LJ
Blood; 1994 Apr; 83(7):1760-8. PubMed ID: 8142644
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the individual and combined reactivities of monoclonal antibodies H25, H366, and MY9 with normal progenitor cells and blast cells from patients with acute myeloblastic leukemia.
Wisniewski D; Strife A; Arlin Z; Knowles R; Lambek C; Gulati S; McHendry B; McKenzie S; Clarkson B
Leukemia; 1989 Jun; 3(6):446-52. PubMed ID: 2657231
[TBL] [Abstract][Full Text] [Related]
13. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia.
Kossman SE; Scheinberg DA; Jurcic JG; Jimenez J; Caron PC
Clin Cancer Res; 1999 Oct; 5(10):2748-55. PubMed ID: 10537338
[TBL] [Abstract][Full Text] [Related]
14. Autologous bone marrow transplantation in acute leukemia with marrow purged with alkyl-lysophospholipid.
Vogler WR; Berdel WE; Olson AC; Winton EF; Heffner LT; Gordon DS
Blood; 1992 Sep; 80(6):1423-9. PubMed ID: 1520869
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic analysis and characterization of CD34+ cells from normal human bone marrow, cord blood, peripheral blood, and mobilized peripheral blood from patients undergoing autologous stem cell transplantation.
Bender JG; Unverzagt K; Walker DE; Lee W; Smith S; Williams S; Van Epps DE
Clin Immunol Immunopathol; 1994 Jan; 70(1):10-8. PubMed ID: 7505211
[TBL] [Abstract][Full Text] [Related]
16. Combined transplantation of allogeneic bone marrow and CD34+ blood cells.
Link H; Arseniev L; Bähre O; Berenson RJ; Battmer K; Kadar JG; Jacobs R; Casper J; Kühl J; Schubert J; Diedrich H; Poliwoda H
Blood; 1995 Oct; 86(7):2500-8. PubMed ID: 7545459
[TBL] [Abstract][Full Text] [Related]
17. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.
Larson RA; Sievers EL; Stadtmauer EA; Löwenberg B; Estey EH; Dombret H; Theobald M; Voliotis D; Bennett JM; Richie M; Leopold LH; Berger MS; Sherman ML; Loken MR; van Dongen JJ; Bernstein ID; Appelbaum FR
Cancer; 2005 Oct; 104(7):1442-52. PubMed ID: 16116598
[TBL] [Abstract][Full Text] [Related]
18. CD33 as a target for selective ablation of acute myeloid leukemia.
Bernstein ID
Clin Lymphoma; 2002 Mar; 2 Suppl 1():S9-11. PubMed ID: 11970770
[TBL] [Abstract][Full Text] [Related]
19. Autologous bone marrow transplantation in high-risk remission T-lineage acute lymphoblastic leukemia using immunotoxins plus 4-hydroperoxycyclophosphamide for marrow purging.
Uckun FM; Kersey JH; Vallera DA; Ledbetter JA; Weisdorf D; Myers DE; Haake R; Ramsay NK
Blood; 1990 Nov; 76(9):1723-33. PubMed ID: 2224122
[TBL] [Abstract][Full Text] [Related]
20. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
